StudyFinder

DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHASTA-3 STUDY)

Recruiting

The purpose of this clinical research study is to look at how safe and effective the study drug, plozasiran, is at lowering triglycerides in people with severe hypertriglyceridemia. Hypertriglyceridemia is a condition where there is too much of a certain kind of fat (called triglycerides) in the blood. In people with severe hypertriglyceridemia, the level of triglycerides is more than 3 times higher than the normal, healthy level. The purpose of this study is to learn how effective the study drug is when given to people with very high triglycerides.

I'm interested

Male or Female
18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosis of severe hypertriglyceridemia (SHTG) with fasting TG levels of ≥ 500 mg/dL
• fasting low density lipoprotein-cholesterol (LDL-C) ≤130 mg/dL
• willing to follow diet counseling and maintain a stable low-fat diet
• on standard of care lipid-lowering medications (exception if medications aren't tolerated)
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• Body mass index (BMI) >45kg/m^2
• used any hepatocyte-targeted small interfering ribonucleic acid (siRNA) that targets lipids and/or triglycerides within the past year
• diagnosis of familial chylomicronemia syndrome (FCS) (type 1 Hyperlipoproteinemia)

Drug: Placebo, Drug: Plozasiran Injection

Diabetes & Endocrine, Heart & Vascular, Prevention & Wellness

Clinics and Surgery Center (CSC), dyslipidemia, high triglycerides, hypertriglyceridemia, triglycerides

Michelle Pitt - henni032@umn.edu
Daniel Duprez
PHASE3
STUDY00022859
See this study on ClinicalTrials.gov

Back